Jennison Associates’s BridgeBio Pharma BBIO Stock Holding History

Jennison Associates’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-30,119	Closed	-$767K	–	582
2024 Q3	$767K	Buy	+30,119	New	+$791K	﹤0.01%	510
2024 Q1	–	Sell	-19,357	Closed	-$781K	–	578
2023 Q4	$781K	Sell	19,357 -944	-5%	-$28.4K	﹤0.01%	519
2023 Q3	$535K	Sell	20,301 -33,589	-62%	-$953K	﹤0.01%	536
2023 Q2	$927K	Buy	53,890 +13,666	+34%	+$206K	﹤0.01%	497
2023 Q1	$667K	Sell	40,224 -58,730	-59%	-$685K	﹤0.01%	544
2022 Q4	$754K	Buy	98,954 +12,048	+14%	+$115K	﹤0.01%	532
2022 Q3	$864K	Buy	+86,906	New	+$903K	﹤0.01%	519

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jennison Associates's BBIO Position: Q4 2024 in Review

Jennison Associates sold out of BridgeBio Pharma (BBIO) in Q4 2024, closing a stake of 30,119 shares — an estimated $767K sold.

Jennison Associates first reported a position in BBIO in Q3 2022 and held it in 7 quarters. The position peaked at $927K in Q2 2023. 263 funds tracked by Wall St. Rank hold BBIO as of Q4 2024.

Jennison Associates reported no remaining BridgeBio Pharma position as of Q4 2024 after selling out during the quarter.
Jennison Associates sold 30,119 BridgeBio Pharma shares in Q4 2024, an estimated $767K.
Jennison Associates first reported a position in BridgeBio Pharma in Q3 2022 and held it in 7 quarters.
Jennison Associates's BridgeBio Pharma position peaked at $927K in Q2 2023.
263 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2024.

Based on Jennison Associates's 13F filing for Q4 2024, filed 24 Jan 2025.